Rhythm Pharmaceuticals Inc.宣布，将与英国国家医疗服务体系（NHS）密切协作，共同敲定针对其药物Imcivree的覆盖指南。这一举措旨在为获得性肥胖症患者提供治疗保障。双方的合作将聚焦于如何精准界定覆盖范围，确保患者能够及时获得这一创新疗法。通过细化指南，他们期望能加速药物纳入医保的进程，从而缓解肥胖症带来的公共健康压力。
Rhythm Pharmaceuticals Inc.宣布，将与英国国家医疗服务体系（NHS）密切协作，共同敲定针对其药物Imcivree的覆盖指南。这一举措旨在为获得性肥胖症患者提供治疗保障。双方的合作将聚焦于如何精准界定覆盖范围，确保患者能够及时获得这一创新疗法。通过细化指南，他们期望能加速药物纳入医保的进程，从而缓解肥胖症带来的公共健康压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.